The American Journal of Managed Care4 小时
New Generation of CAR T May Elicit Improved CR Rates in CLL
T-cell therapy yielded encouraging response rates and safety findings among patients with relapsed or refractory chronic ...
PharmiWeb1 天
Understanding CAR T-Cell Therapy: A Revolutionary Approach to Cancer Treatment
CAR T-cell therapy represents a groundbreaking advancement in the field of oncology, particularly in the treatment of certain types of blood cancers such as leukemia and lymphoma. This innovative ...
Pharmaceutical Technology4 天
Ruxolitinib phosphate by Incyte for Coronavirus Disease 2019 (COVID-19) Associated Cytokine ...
Ruxolitinib phosphate is under clinical development by Incyte and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Associated Cytokine Release Syndrome.
Too Old to Operate17 天
Hemadsorption in Cardiac Surgery and Cytokine Reduction During Recovery
The following is a summary of “REmoval of cytokines during CArdiac surgery (RECCAS): a randomised controlled trial,” published in the December 2024 issue of Critical Care by Hohn et al.
MedPage Today27 天
Dual Targeted CAR-T Yields 99% Response Rate in Pediatric ALL
Cytokine release syndrome (CRS) developed in all patients, including grade 3/4 events in nearly half. "Bicistronic CD19/CD22-targeted CAR T-cell therapy is a safe and effective regimen which ...
EurekAlert!15 天
New review explores advances in alcohol-associated liver disease
A recent review published in eGastroenterology discusses recent advancements in understanding alcohol-associated liver ...